Simplex Trading
BBIO icon

Simplex Trading’s BridgeBio Pharma BBIO Stock Holding History

Simplex Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5M Buy
74,000
+52,600
+246% +$3.81M ﹤0.01% 1051
2025
Q4 		$1.64M Sell
21,400
-18,400
-46% -$1.21M ﹤0.01% 2143
2025
Q3 		$2.07M Sell
39,800
-55,900
-58% -$2.73M ﹤0.01% 2291
2025
Q2 		$4.13M Buy
95,700
+24,800
+35% +$902K ﹤0.01% 1504
2025
Q1 		$2.45M Sell
70,900
-80,600
-53% -$2.72M ﹤0.01% 1856
2024
Q4 		$4.16M Buy
151,500
+13,100
+9% +$339K ﹤0.01% 1613
2024
Q3 		$3.52M Sell
138,400
-144,200
-51% -$3.79M ﹤0.01% 1780
2024
Q2 		$7.16M Buy
282,600
+75,200
+36% +$2.06M ﹤0.01% 1224
2024
Q1 		$6.41M Buy
207,400
+87,900
+74% +$2.99M ﹤0.01% 1415
2023
Q4 		$4.82M Sell
119,500
-162,800
-58% -$4.89M ﹤0.01% 1589
2023
Q3 		$7.44M Buy
282,300
+66,600
+31% +$1.89M 0.01% 1085
2023
Q2 		$3.71M Sell
215,700
-432,900
-67% -$6.51M ﹤0.01% 1518
2023
Q1 		$10.8M Buy
648,600
+640,500
+7,907% +$7.47M 0.01% 858
2022
Q4 		$61K Sell
8,100
-16,700
-67% -$160K ﹤0.01% 5622
2022
Q3 		$246K Sell
24,800
-1,000
-4% -$10.4K ﹤0.01% 4341
2022
Q2 		$234K Buy
25,800
+15,300
+146% +$128K ﹤0.01% 4419
2022
Q1 		$106K Sell
10,500
-78,000
-88% -$801K ﹤0.01% 6046
2021
Q4 		$1.48M Buy
88,500
+86,800
+5,106% +$3.67M ﹤0.01% 2376
2021
Q3 		$108K Hold
1,700
– – ﹤0.01% 6509
2021
Q2 		$103K Buy
1,700
+1,648
+3,169% +$94.1K ﹤0.01% 6686
2021
Q1 		$320K Buy
52
+47
+940% +$3.08K ﹤0.01% 4070
2020
Q4 		$35K Sell
5
-42
-89% -$2.03K ﹤0.01% 6518
2020
Q3 		$176K Sell
47
-5
-10% -$157 ﹤0.01% 4273
2020
Q2 		$169K Sell
52
-42
-45% -$1.28K ﹤0.01% 4178
2020
Q1 		$272K Buy
+94
New +$2.92K ﹤0.01% 3242

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's BBIO Position: Q1 2026 in Review

Simplex Trading increased its BridgeBio Pharma (BBIO) stake by 125% in Q1 2026, buying an estimated $1.67M and bringing the position to 41,434 shares worth $3.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Simplex Trading first reported a position in BBIO in Q1 2020 and has held it in 12 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Simplex Trading held 41,434 shares of BridgeBio Pharma worth $3.08M as of Q1 2026.
  • Simplex Trading bought 23,022 BridgeBio Pharma shares in Q1 2026, an estimated $1.67M.
  • BridgeBio Pharma made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #1479 holding.
  • Simplex Trading first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 12 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.